Navigation Links
Alexza to Announce 2011 Second Quarter Financial Results on Monday, August 8, 2011
Date:7/26/2011

MOUNTAIN VIEW, Calif., July 26, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will report financial results for the quarter ended June 30, 2011, on Monday, August 8, 2011, following the close of the U.S. financial markets.  Alexza also announced that the resubmission of its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) is now planned for Monday, August 8, 2011.  The Company completed the writing of the NDA sections earlier this week.  The documents have been transferred to Alexza's electronic submission vendor who is assembling and processing the files for eCTD (electronic Common Technical Document) submission to the FDA.

"The entire Alexza organization has worked diligently toward the resubmission of our AZ-004 NDA," said Thomas B. King, Alexza President and CEO.  "Our employees have combined their skills with those of some outstanding outside consultants and advisors, who are experts in the key areas of focus of our resubmission.  In addition to the data in our original NDA, our resubmitted NDA contains data from our successfully completed human factors study, stability data from new production batches manufactured late last year, and a comprehensive REMS proposal and draft labeling for AZ-004."

On Monday, August 8, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time, the Company will host an investor conference call and live webcast to provide a company update, as well as to discuss the financial results.  The conference call, live webcast and archived replay are open to all interested parties.

To access the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" link.  Please join the call at least 15 minutes prior to the start of the call to ensure time for any software do
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
2. Alexza to Present at the MDB Bright Lights Conference 2011
3. Alexza Prices $16.1 Million Registered Direct Offering
4. Alexza Reports 2010 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
5. Alexza to Announce 2010 Year-End Financial Results on Tuesday, March 15, 2011
6. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
7. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
8. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
9. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
10. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
11. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... 26, 2011 Masimo (NASDAQ: MASI ) today ... Goldman Sachs 32nd Annual Global Healthcare Conference at Terranea in ... 8:40 a.m. Pacific Time.  A live audiocast of the presentation ... .  A replay of the audiocast will be available following ...
... OTC Markets Group Inc. (OTCQX: OTCM), ... the world,s largest electronic marketplace for broker-dealers to trade ... (TSX.V: VRS; OTCQX: VRSEF), a medical device company ... of cancer, is now trading on the OTC market,s ...
Cached Medicine Technology:Masimo to Present at Goldman Sachs 32nd Annual Global Healthcare Conference 2Verisante Technology Inc. Joins OTCQX 2
(Date:4/24/2014)... more than 15 years ago, the PTEN gene has ... the onset and progression of numerous cancers. Consequently, when ... grow unchecked and cancer can develop. , Now a ... Center (BIDMC) helps explain more precisely how PTEN exerts ... can set cells on a cancerous course. The new ...
(Date:4/24/2014)... Benefits often coexist with the negative and stressful outcomes ... later diagnosed with a life-limiting illness, says a recent ... Waterloo. , While the challenges are numerous and life-changing ... who participated in the Waterloo-led research reported positive outcomes ... findings appear in the most recent issue of the ...
(Date:4/24/2014)... the Center for BrainHealth will bring together national ... brain-related challenges at its inaugural Brain Health Summit, ... Featured speakers will include Dr. Sandra Bond Chapman, ... BrainHealth, U.S. Senator Chuck Grassley (R-IA), U.S. Representative ... Secretary for Policy and Early Learning, U.S. Department ...
(Date:4/24/2014)... of prescription opioid overdose deaths was outlined yesterday in ... leaders of agencies in the U.S. Department of Health ... care providers to expand their use of medications to ... a number of misperceptions that have limited access to ... medications can be used in combination with behavior therapies ...
(Date:4/24/2014)... one of 30 grants from the National Cancer Institute ... in its new National Clinical Trials Network ... investigators charged with distributing resources in a more effective ... reflects recommendations from a 2010 Institute of Medicine ... Faster design, launch, and completion of clinical ...
Breaking Medicine News(10 mins):Health News:Surprising new insights into the PTEN tumor suppressor gene 2Health News:Surprising new insights into the PTEN tumor suppressor gene 3Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3
... of the new health reform in China have been ... one of the most important policies ,The National Essential ... solve the high cost of drugs in China through ... drug prices that cover a wide range of diseases ...
... Million Contribution Mark to Support Families Living with Autism and Other ... ... -- Safeway (NYSE:SWY) captures Easter Seals, highest ... for children and adults with autism and other disabilities in 2009 ...
... celebrating their 50th year anniversary this month. Founded in 1959, ... various industries. In the 1970s, Key Instruments began focusing exclusively ... flow meters, and then expanded to include molded flow meters, ... ...
... tattoo to fit horizontal tummy tuck and c-section scars. It is made ... was designed to last 1-3 days. It can be applied and removed ... ... ScarArt, an innovative new company specializing in adhesive products used to conceal ...
... provide affordable and timely transcription services , ... ... Inc., the nation,s leading provider of transcription services to group ... will incorporate M*Modal,s Conversational Documentation Services (CDS) ...
... NuSil Technology announced a definitive agreement to acquire the pharmaceutical ... ... Carpinteria, Calif. (Vocus) May 21, 2009 -- NuSil ... silicone compounds for the healthcare and pharmaceutical industries, announced a ...
Cached Medicine News:Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 2Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 2Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 4Health News:Key Instruments Celebrates 50 Year Anniversary 2Health News:Key Instruments Celebrates 50 Year Anniversary 3Health News:ScarArt -Creatively Camouflage Abdominal Scars 2Health News:MxSecure Expands Offerings with M*Modal Speech Recognition Solution 2Health News:MxSecure Expands Offerings with M*Modal Speech Recognition Solution 3Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 2Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: